AR and prostate carcinoma: Preclinical studies have shown that the Bcl-2 promoter has ARE binding sites and that ligand activation of AR in prostate cancer cell lines directly represses Bcl-2 transcription (30) and COX2 expression via modulation of NF-κB signaling (31).